Harrow 2025 Q2 Earnings Net Income Surges 177.2%

Harrow reported its Q2 2025 earnings on August 11, 2025, delivering a strong performance that significantly exceeded expectations. The company posted a net income of $5 million, representing a remarkable 177.2% turnaround from a $-6.47 million loss in the same period last year. Earnings per share (EPS) rose from a loss of $0.18 to a profit of $0.14, highlighting a 177.8% positive shift. This impressive financial comeback positions Harrow for continued growth and strengthened capital.

Revenue
Harrow's total revenue surged 30.3% year-over-year to $63.66 million in Q2 2025, compared to $48.87 million in Q2 2024. Product sales accounted for $63.66 million, representing the vast majority of the company's revenue. Other revenue sources, including non-product sales, contributed an additional $85,000. Together, these segments brought Harrow's total revenues to $63.74 million, showcasing a well-rounded and robust performance across its business lines.

Earnings/Net Income
The company’s earnings turnaround is a testament to its improved financial management and operational efficiency. Harrow moved from a loss of $6.47 million in Q2 2024 to a net profit of $5 million in Q2 2025, representing an impressive 177.2% increase. Similarly, EPS improved from a loss of $0.18 to a profit of $0.14, a 177.8% improvement, indicating a substantial positive shift in profitability. This strong earnings performance reflects the company's strategic initiatives and growing revenue streams.

Price Action
Despite the positive earnings report, Harrow’s stock price experienced mixed short-term movements. During the latest trading day, the stock edged down 2.60%, but it gained 0.96% over the past full trading week and climbed 7.55% month-to-date. These fluctuations reflect investor sentiment and market dynamics following the earnings release.

Post-Earnings Price Action Review
A strategy of buying Harrow shares 30 days after the Q2 earnings report has yielded strong historical returns. Over the past three years, this approach generated a total return of 318.29%, outperforming the 45.70% benchmark by 272.59%. The strategy’s compound annual growth rate (CAGR) of 63.77% and a maximum drawdown of 0.00% underscore its effectiveness and risk-controlled nature. This performance highlights Harrow’s potential as a long-term investment with consistent returns.

CEO Commentary
Mark L. Baum, CEO of Harrow, emphasized the company’s strong Q2 2025 performance, noting the positive impact of VEVYE’s 3% market share gain and 66% sequential prescription growth. He highlighted the VAFA program and expanded pharmacy network as key drivers for improving ASP and revenue growth. The CEO also expressed confidence in the commercial platform, including new revenue streams like Samsung biosimilars and BYQLOVI, which are expected to drive profitability with minimal incremental costs. IHEEZO is anticipated to deliver record performance for the remainder of 2025, and TRIESENCE is expected to align with its $100 million annual revenue forecast following the ocular inflammation launch.

Guidance
Harrow expects to exceed $280 million in total revenue for 2025 and anticipates quarterly revenues to surpass $100 million as VEVYE’s ASP stabilizes with an upward bias. IHEEZO is forecasted to deliver record performance for the remainder of the year, and TRIESENCE is expected to align with its $100 million annual revenue acquisition thesis after the ocular inflammation launch. The CEO reiterated that the branded portfolio and ImprimisRx are on track to deliver results in line with the 2025 forecast.

Additional News
In the week leading up to Harrow’s Q2 earnings, several notable developments emerged. The U.S. government announced a new round of support for consumer and service sector loans, including targeted fiscal incentives for purchases under $50,000. Meanwhile, Trump’s administration continued its engagement with Chinese trade policies, with the president emphasizing potential increases in U.S. agricultural exports. In the tech sector, the 2025 World Robot Conference highlighted advancements in robot applications across industries, further reinforcing the potential for innovation in Harrow’s operating environment.